Madrigal Pharmaceuticals (MDGL) Receivables - Net (2024 - 2026)

Madrigal Pharmaceuticals (MDGL) has 3 years of Receivables - Net data on file, last reported at $187.4 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $187.4 million, up 205.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $187.4 million (up 205.0% YoY), and the FY2025 annual result was $134.5 million, up 149.85% from the prior year.
• Receivables - Net advanced to $187.4 million in Q1 2026 per MDGL's latest filing, from $134.5 million in the prior quarter.
• Over five years, Receivables - Net peaked at $187.4 million in Q1 2026 and troughed at $6.9 million in Q2 2024.
• A 3-year average of $83.4 million and a median of $70.3 million in 2025 frame the typical range for Receivables - Net.
• On a YoY basis, Receivables - Net climbed as much as 1048.44% in 2025 and fell as far as 149.85% in 2025.
• A 3-year view of Receivables - Net shows it stood at $53.8 million in 2024, then surged by 149.85% to $134.5 million in 2025, then soared by 39.32% to $187.4 million in 2026.
• Business Quant data shows MDGL's Receivables - Net at $187.4 million in Q1 2026, $134.5 million in Q4 2025, and $113.3 million in Q3 2025.